Jeffrey Lawrence Schwartz
CIK 1702957 · Chief Executive Officer · last filed 2026-09-10
Jeffrey Lawrence Schwartz is a Chief Executive Officer who has filed 19 SEC Form 4 insider transactions across 7 companies since 2017. The most recent filing, for KMTS, was dated Sep 10, 2026. Across all open-market trades the lifetime net is −$294.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $787.1M across reported positions. 20 SEC filings were submitted jointly with Bain Capital Life Sciences Investors, LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SWTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 CLARENDON STRERET
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KMTS | Director | 25,179,357 | $29.42 | $740.78M | -$97.9K | 2 | 2026-09-10 |
| RPID | Director | 8,448,860 | $0.79 | $6.63M | $0 | 4 | 2024-05-28 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 3,091,879 | $46.99 | $145.29M | -$320.07M | 8 | 2023-05-25 |
| BCLS Acquisition Corp. (BLSA) Delisted | Chief Executive Officer | 487,500 | $10.04 | $4.89M | $0 | 1 | 2020-10-26 |
| ANNX | 10%+ Owner | 2,841,628 | $3.70 | $10.51M | $40.80M | 1 | 2020-07-28 |
| REPL | 10%+ Owner | 2,338,968 | $12.47 | $29.17M | $45.00M | 1 | 2018-07-26 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 994,363 | $0.55 | $546.9K | -$60.15M | 1 | 2017-12-19 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-10 | KMTS | Mixed | +3,327 | -$97.9K | EDGAR |
| 2026-09-08 | KMTS | Notice (144) | −3,890 | -$97.9K | EDGAR |
| 2025-09-08 | KMTS | Grant (A) | +10,909 | $0 | EDGAR |
| 2024-05-28 | RPID | Grant (A) | +14,300 | $0 | EDGAR |
| 2023-05-25 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +4,648 | $0 | EDGAR |
| 2023-05-05 | RPID | Grant (A) | — | $0 | EDGAR |
| 2023-03-20 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −1,750,000 | -$49.88M | EDGAR |
| 2022-06-10 | RPID | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +4,818 | $0 | EDGAR |
| 2021-08-12 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −4,000,000 | -$281.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.